[{"id":"2f9874c4-f677-4e33-b8c8-e0765095f8b3","acronym":"DUAL-OV-CAR-NK","url":"https://clinicaltrials.gov/study/NCT07480954","created_at":"2026-03-28T01:39:31.330Z","updated_at":"2026-03-28T01:39:31.330Z","phase":"Phase 1/2","brief_title":"Dual-Targeting CAR-NK Cells for Recurrent Ovarian Cancer (MSLN, FRα, MUC16)","source_id_and_acronym":"NCT07480954 - DUAL-OV-CAR-NK","lead_sponsor":"Beijing Biotech","biomarkers":" FOLR1 • MSLN • MUC16","pipe":"","alterations":" ","tags":["FOLR1 • MSLN • MUC16"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e cyclophosphamide • fludarabine IV"],"overall_status":"Recruiting","enrollment":" Enrollment 36","initiation":"Initiation: 02/04/2026","start_date":" 02/04/2026","primary_txt":" Primary completion: 02/17/2027","primary_completion_date":" 02/17/2027","study_txt":" Completion: 05/17/2028","study_completion_date":" 05/17/2028","last_update_posted":"2026-03-18"},{"id":"37515089-1ee4-4286-99b0-7bb0298fc653","acronym":"","url":"https://clinicaltrials.gov/study/NCT07472153","created_at":"2026-03-28T01:41:57.745Z","updated_at":"2026-03-28T01:41:57.745Z","phase":"Phase 2/3","brief_title":"PD-1 (Programmed Death-1) Versus PD-L1 (Programmed Death-ligand 1) Immune Check Point Inhibitors Combined With Chemotherapy, With or Without Bevacizumab, In Patients With Metastatic, Persistent Or Recurrent Cervical Cancer","source_id_and_acronym":"NCT07472153","lead_sponsor":"N.N. Alexandrov National Cancer Centre","biomarkers":" PD-L1","pipe":" | ","alterations":" PD-L1 expression","tags":["PD-L1"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e PD-L1 expression"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Avastin (bevacizumab) • cisplatin • carboplatin • paclitaxel"],"overall_status":"Recruiting","enrollment":" Enrollment 120","initiation":"Initiation: 07/01/2025","start_date":" 07/01/2025","primary_txt":" Primary completion: 06/30/2030","primary_completion_date":" 06/30/2030","study_txt":" Completion: 06/30/2033","study_completion_date":" 06/30/2033","last_update_posted":"2026-03-16"},{"id":"8fac6d48-bf25-4ede-b0bd-19869334e342","acronym":"","url":"https://clinicaltrials.gov/study/NCT07472140","created_at":"2026-03-28T01:41:57.184Z","updated_at":"2026-03-28T01:41:57.184Z","phase":"Phase 2/3","brief_title":"PARP (Poly (ADP-ribose) Polymerase) Inhibitor With or Without Angiogenesis Inhibitor in Homologous Recombination Deficient Primary Ovarian Cancer, Fallopian-Tube Cancer, or Primary Peritoneal Cancer","source_id_and_acronym":"NCT07472140","lead_sponsor":"N.N. Alexandrov National Cancer Centre","biomarkers":" HRD","pipe":" | ","alterations":" HRD","tags":["HRD"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e HRD"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Avastin (bevacizumab) • paclitaxel"],"overall_status":"Recruiting","enrollment":" Enrollment 120","initiation":"Initiation: 07/01/2025","start_date":" 07/01/2025","primary_txt":" Primary completion: 06/30/2033","primary_completion_date":" 06/30/2033","study_txt":" Completion: 06/30/2033","study_completion_date":" 06/30/2033","last_update_posted":"2026-03-16"},{"id":"fd4f177e-f85d-440b-907a-20a6e87e3329","acronym":"PRO-ACTIVE","url":"https://clinicaltrials.gov/study/NCT07469709","created_at":"2026-03-28T01:44:12.315Z","updated_at":"2026-03-28T01:44:12.315Z","phase":"","brief_title":"A Study of Biological, Genetic, and Constitutional Factors and Non-invasive Monitoring to Assess Personal Cancer Risks","source_id_and_acronym":"NCT07469709 - PRO-ACTIVE","lead_sponsor":"Fondazione del Piemonte per l'Oncologia","biomarkers":" BRCA","pipe":"","alterations":" ","tags":["BRCA"],"overall_status":"Recruiting","enrollment":" Enrollment 850","initiation":"Initiation: 02/01/2024","start_date":" 02/01/2024","primary_txt":" Primary completion: 05/01/2027","primary_completion_date":" 05/01/2027","study_txt":" Completion: 12/31/2027","study_completion_date":" 12/31/2027","last_update_posted":"2026-03-13"},{"id":"11f1db6a-6822-4ad4-9456-501ec049e598","acronym":"BEND-MBEC","url":"https://clinicaltrials.gov/study/NCT07189702","created_at":"2025-09-27T08:41:02.423Z","updated_at":"2025-09-27T08:41:02.423Z","phase":"","brief_title":"Plant-Based Nutrition for Breast or Endometrial Cancer","source_id_and_acronym":"NCT07189702 - BEND-MBEC","lead_sponsor":"University of Rochester","biomarkers":" IGF1","pipe":"","alterations":" ","tags":["IGF1"],"overall_status":"Not yet recruiting","enrollment":" Enrollment 60","initiation":"Initiation: 12/01/2025","start_date":" 12/01/2025","primary_txt":" Primary completion: 12/01/2028","primary_completion_date":" 12/01/2028","study_txt":" Completion: 12/01/2029","study_completion_date":" 12/01/2029","last_update_posted":"2025-09-24"},{"id":"0ad91159-5e74-4841-9bb6-f71f53c01cf6","acronym":"","url":"https://clinicaltrials.gov/study/NCT07181720","created_at":"2025-09-20T07:06:00.818Z","updated_at":"2025-09-20T07:06:00.818Z","phase":"Phase 1","brief_title":"Safety and Efficacy of CD70-Targeted CAR-T Therapy in CD70-Positive Advanced Solid Tumors: A Clinical Trial","source_id_and_acronym":"NCT07181720","lead_sponsor":"Chongqing Precision Biotech Co., Ltd","biomarkers":" CD70","pipe":"","alterations":" ","tags":["CD70"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e cyclophosphamide • fludarabine IV • CD70 CAR-T"],"overall_status":"Recruiting","enrollment":" Enrollment 90","initiation":"Initiation: 09/12/2025","start_date":" 09/12/2025","primary_txt":" Primary completion: 03/31/2028","primary_completion_date":" 03/31/2028","study_txt":" Completion: 05/31/2028","study_completion_date":" 05/31/2028","last_update_posted":"2025-09-18"},{"id":"b3d11c4b-a1ab-423b-985e-6d16fd2ac00a","acronym":"","url":"https://clinicaltrials.gov/study/NCT07179757","created_at":"2025-09-20T07:05:19.549Z","updated_at":"2025-09-20T07:05:19.549Z","phase":"","brief_title":"Clinical Outcomes and Quality of Life in Patients With Locally Advanced Vulvovaginal Cancers: Ambispective Registration Study.","source_id_and_acronym":"NCT07179757","lead_sponsor":"Tata Memorial Hospital","biomarkers":" PD-L1","pipe":"","alterations":" ","tags":["PD-L1"],"overall_status":"Recruiting","enrollment":" Enrollment 200","initiation":"Initiation: 10/30/2021","start_date":" 10/30/2021","primary_txt":" Primary completion: 10/01/2025","primary_completion_date":" 10/01/2025","study_txt":" Completion: 10/01/2026","study_completion_date":" 10/01/2026","last_update_posted":"2025-09-18"},{"id":"f548789f-e984-493e-8c25-7196761bc8df","acronym":"","url":"https://clinicaltrials.gov/study/NCT07153952","created_at":"2025-09-06T13:40:49.515Z","updated_at":"2025-09-06T13:40:49.515Z","phase":"Phase 1/2","brief_title":"RT for Adenocarcinoma/Adenosquamous Carcinoma","source_id_and_acronym":"NCT07153952","lead_sponsor":"Peking Union Medical College Hospital","biomarkers":" PD-L1","pipe":"","alterations":" ","tags":["PD-L1"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e cisplatin • carboplatin • paclitaxel"],"overall_status":"Active, not recruiting","enrollment":" Enrollment 60","initiation":"Initiation: 01/01/2025","start_date":" 01/01/2025","primary_txt":" Primary completion: 01/01/2027","primary_completion_date":" 01/01/2027","study_txt":" Completion: 01/01/2028","study_completion_date":" 01/01/2028","last_update_posted":"2025-09-04"},{"id":"716dc364-32b8-4cd4-ad8c-813b9359535b","acronym":"PB-PD1R-SCC","url":"https://clinicaltrials.gov/study/NCT07147361","created_at":"2025-09-07T01:05:27.471Z","updated_at":"2025-09-07T01:05:27.471Z","phase":"","brief_title":"Predictive Biomarkers for PD-1 Inhibitor Response in Squamous Cell Carcinoma","source_id_and_acronym":"NCT07147361 - PB-PD1R-SCC","lead_sponsor":"Cancer Institute and Hospital, Chinese Academy of Medical Sciences","biomarkers":" PD-L1","pipe":"","alterations":" ","tags":["PD-L1"],"overall_status":"Active, not recruiting","enrollment":" Enrollment 800","initiation":"Initiation: 04/28/2022","start_date":" 04/28/2022","primary_txt":" Primary completion: 07/31/2026","primary_completion_date":" 07/31/2026","study_txt":" Completion: 07/31/2027","study_completion_date":" 07/31/2027","last_update_posted":"2025-08-29"},{"id":"c72f3a57-80b1-4204-bf22-b374de81ba27","acronym":"","url":"https://clinicaltrials.gov/study/NCT07114653","created_at":"2025-08-16T14:08:30.041Z","updated_at":"2025-08-16T14:08:30.041Z","phase":"","brief_title":"The Role of POLE Mutation in High Risk Endometrial Cancer.","source_id_and_acronym":"NCT07114653","lead_sponsor":"Far Eastern Memorial Hospital","biomarkers":" POLE","pipe":" | ","alterations":" POLE mutation","tags":["POLE"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e POLE mutation"],"overall_status":"Recruiting","enrollment":" Enrollment 150","initiation":"Initiation: 09/01/2025","start_date":" 09/01/2025","primary_txt":" Primary completion: 12/31/2026","primary_completion_date":" 12/31/2026","study_txt":" Completion: 12/31/2026","study_completion_date":" 12/31/2026","last_update_posted":"2025-08-11"},{"id":"0dede7b9-ee1b-410d-9416-c7e60518928b","acronym":"NSGO","url":"https://clinicaltrials.gov/study/NCT03267589","created_at":"2025-08-02T14:05:36.136Z","updated_at":"2025-08-02T14:05:36.136Z","phase":"Phase 2","brief_title":"Trial in Patients With Relapsed Ovarian Cancer","source_id_and_acronym":"NCT03267589 - NSGO","lead_sponsor":"Nordic Society of Gynaecological Oncology - Clinical Trials Unit","biomarkers":" CD73","pipe":"","alterations":" ","tags":["CD73"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Imfinzi (durvalumab) • oleclumab (MEDI9447) • tavolixizumab (MEDI0562)"],"overall_status":"Completed","enrollment":" Enrollment 25","initiation":"Initiation: 05/14/2018","start_date":" 05/14/2018","primary_txt":" Primary completion: 10/19/2021","primary_completion_date":" 10/19/2021","study_txt":" Completion: 10/19/2021","study_completion_date":" 10/19/2021","last_update_posted":"2025-07-29"},{"id":"e6296b14-457a-49ec-b305-921eba77b4de","acronym":"","url":"https://clinicaltrials.gov/study/NCT07088588","created_at":"2025-08-02T14:24:39.476Z","updated_at":"2025-08-02T14:24:39.476Z","phase":"Phase 1","brief_title":"Study of SYN608 for the Treatment of Advanced or Metastatic Solid Tumors","source_id_and_acronym":"NCT07088588","lead_sponsor":"Hangzhou SynRx Therapeutics Biomedical Technology Co., Ltd","biomarkers":" BRCA","pipe":"","alterations":" ","tags":["BRCA"],"overall_status":"Not yet recruiting","enrollment":" Enrollment 105","initiation":"Initiation: 07/31/2025","start_date":" 07/31/2025","primary_txt":" Primary completion: 07/31/2028","primary_completion_date":" 07/31/2028","study_txt":" Completion: 10/31/2028","study_completion_date":" 10/31/2028","last_update_posted":"2025-07-28"},{"id":"5ab70206-a4cc-4b5d-b4d4-1bcadd6d07f9","acronym":"BR-OLP-CT-101","url":"https://clinicaltrials.gov/study/NCT07069335","created_at":"2025-07-19T14:11:52.627Z","updated_at":"2025-07-19T14:11:52.627Z","phase":"Phase 1","brief_title":"A Bioequivalence Study to Evaluate Pharmacokinetics and Safety of BR2022 and BR2022-1 in Patients With Deleterious or Suspected Deleterious Germline BRCA-Mutated Advanced Ovarian Cancer","source_id_and_acronym":"NCT07069335 - BR-OLP-CT-101","lead_sponsor":"Boryung Pharmaceutical Co., Ltd","biomarkers":" BRCA","pipe":"","alterations":" ","tags":["BRCA"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Lynparza (olaparib)"],"overall_status":"Recruiting","enrollment":" Enrollment 24","initiation":"Initiation: 06/17/2025","start_date":" 06/17/2025","primary_txt":" Primary completion: 05/15/2026","primary_completion_date":" 05/15/2026","study_txt":" Completion: 05/15/2026","study_completion_date":" 05/15/2026","last_update_posted":"2025-07-16"},{"id":"4298f366-bf0a-48de-9ba6-e0866564f4f9","acronym":"GerEC","url":"https://clinicaltrials.gov/study/NCT07066969","created_at":"2025-07-19T14:16:13.916Z","updated_at":"2025-07-19T14:16:13.916Z","phase":"","brief_title":"Prevalence of Germline Alterations in Actionable Genes in Endometrial Cancer","source_id_and_acronym":"NCT07066969 - GerEC","lead_sponsor":"European Institute of Oncology","biomarkers":" BRCA","pipe":"","alterations":" ","tags":["BRCA"],"overall_status":"Not yet recruiting","enrollment":" Enrollment 20","initiation":"Initiation: 09/01/2025","start_date":" 09/01/2025","primary_txt":" Primary completion: 04/01/2027","primary_completion_date":" 04/01/2027","study_txt":" Completion: 04/01/2027","study_completion_date":" 04/01/2027","last_update_posted":"2025-07-15"},{"id":"c13b4cf9-274e-41ee-98c2-c2c6b58c5ea0","acronym":"","url":"https://clinicaltrials.gov/study/NCT07065552","created_at":"2025-07-19T14:15:38.690Z","updated_at":"2025-07-19T14:15:38.690Z","phase":"Phase 1","brief_title":"Tirzepatide in Obesity-Driven Endometrial Cancer","source_id_and_acronym":"NCT07065552","lead_sponsor":"UNC Lineberger Comprehensive Cancer Center","biomarkers":" IGF1","pipe":"","alterations":" ","tags":["IGF1"],"overall_status":"Not yet recruiting","enrollment":" Enrollment 20","initiation":"Initiation: 07/01/2025","start_date":" 07/01/2025","primary_txt":" Primary completion: 07/01/2028","primary_completion_date":" 07/01/2028","study_txt":" Completion: 07/01/2028","study_completion_date":" 07/01/2028","last_update_posted":"2025-07-15"},{"id":"a24dd70d-457e-4bf3-b1b4-2106aa67a692","acronym":"","url":"https://clinicaltrials.gov/study/NCT07064018","created_at":"2025-07-19T14:18:32.626Z","updated_at":"2025-07-19T14:18:32.626Z","phase":"Phase 1/2","brief_title":"Trial of Single Protein Encapsulated Doxorubicin, SPEDOX-6 in Advanced Malignancies","source_id_and_acronym":"NCT07064018","lead_sponsor":"University of California, Irvine","biomarkers":" KRAS","pipe":"","alterations":" ","tags":["KRAS"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Neulasta (pegfilgrastim) • Neupogen (filgrastim)"],"overall_status":"Recruiting","enrollment":" Enrollment 67","initiation":"Initiation: 04/30/2025","start_date":" 04/30/2025","primary_txt":" Primary completion: 12/31/2029","primary_completion_date":" 12/31/2029","study_txt":" Completion: 12/31/2031","study_completion_date":" 12/31/2031","last_update_posted":"2025-07-14"},{"id":"f13e82aa-caf5-4f36-9021-170e80729eb1","acronym":"","url":"https://clinicaltrials.gov/study/NCT07061977","created_at":"2025-07-19T14:14:48.551Z","updated_at":"2025-07-19T14:14:48.551Z","phase":"Phase 3","brief_title":"Induction Chemotherapy Followed by Pembrolizumab Before Chemoradiation and Pembrolizumab Maintenance Compared to Standard Chemoradiation With Pembrolizumab Followed by Pembrolizumab Maintenance in High-Risk Cervical Cancer","source_id_and_acronym":"NCT07061977","lead_sponsor":"National Cancer Institute (NCI)","biomarkers":" PD-L1","pipe":"","alterations":" ","tags":["PD-L1"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Keytruda (pembrolizumab) • cisplatin • carboplatin"],"overall_status":"Not yet recruiting","enrollment":" Enrollment 336","initiation":"Initiation: 09/19/2025","start_date":" 09/19/2025","primary_txt":" Primary completion: 12/31/2030","primary_completion_date":" 12/31/2030","study_txt":" Completion: 12/31/2030","study_completion_date":" 12/31/2030","last_update_posted":"2025-07-14"},{"id":"1d278134-0537-4b56-865d-be1ee7a40e61","acronym":"IREN","url":"https://clinicaltrials.gov/study/NCT07041606","created_at":"2025-06-28T13:39:22.517Z","updated_at":"2025-06-28T13:39:22.517Z","phase":"","brief_title":"An Observational Study of Molecular profIling of Advanced and aggRessive ENdometrial Cancer and 1-st Line Treatment Approaches in Russian Federation","source_id_and_acronym":"NCT07041606 - IREN","lead_sponsor":"AstraZeneca","biomarkers":" PD-L1","pipe":" | ","alterations":" MSI-H/dMMR","tags":["PD-L1"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e MSI-H/dMMR"],"overall_status":"Not yet recruiting","enrollment":" Enrollment 500","initiation":"Initiation: 06/30/2025","start_date":" 06/30/2025","primary_txt":" Primary completion: 06/30/2027","primary_completion_date":" 06/30/2027","study_txt":" Completion: 06/30/2027","study_completion_date":" 06/30/2027","last_update_posted":"2025-06-27"},{"id":"2cd0bb28-fe10-4b8b-9287-18ad8a95d0b3","acronym":"","url":"https://clinicaltrials.gov/study/NCT03990233","created_at":"2025-06-28T13:37:59.942Z","updated_at":"2025-06-28T13:37:59.942Z","phase":"Phase 1","brief_title":"A Trial of BI 765063 Monotherapy and in Combination With BI 754091 in Patients With Advanced Solid Tumours","source_id_and_acronym":"NCT03990233","lead_sponsor":"OSE Immunotherapeutics","biomarkers":" SIRPA","pipe":"","alterations":" ","tags":["SIRPA"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e ezabenlimab (BI 754091) • BI 765063"],"overall_status":"Completed","enrollment":" Enrollment 100","initiation":"Initiation: 04/16/2019","start_date":" 04/16/2019","primary_txt":" Primary completion: 04/17/2023","primary_completion_date":" 04/17/2023","study_txt":" Completion: 04/30/2025","study_completion_date":" 04/30/2025","last_update_posted":"2025-06-26"},{"id":"5519adeb-c62d-4a9c-b422-ec19e699bf0f","acronym":"","url":"https://clinicaltrials.gov/study/NCT07039552","created_at":"2025-06-28T13:38:59.714Z","updated_at":"2025-06-28T13:38:59.714Z","phase":"","brief_title":"Development and Validation of an Ovarian Cancer Risk Prediction Model for Family Members of Ovarian Cancer Probands","source_id_and_acronym":"NCT07039552","lead_sponsor":"Peking University Third Hospital","biomarkers":" BRCA2 • BRCA","pipe":"","alterations":" ","tags":["BRCA2 • BRCA"],"overall_status":"Recruiting","enrollment":" Enrollment 10000","initiation":"Initiation: 01/01/2016","start_date":" 01/01/2016","primary_txt":" Primary completion: 12/30/2028","primary_completion_date":" 12/30/2028","study_txt":" Completion: 12/30/2035","study_completion_date":" 12/30/2035","last_update_posted":"2025-06-26"},{"id":"277ff408-67f7-4d82-ab62-08c41100ac4a","acronym":"","url":"https://clinicaltrials.gov/study/NCT07006103","created_at":"2025-06-07T14:39:04.179Z","updated_at":"2025-06-07T14:39:04.179Z","phase":"","brief_title":"PRECISION MEDICINE APPLIED TO THE STUDY OF ENDOMETRIAL CANCER: APPLICATION OF NGS FOR MOLECULAR CLASSIFICATION.","source_id_and_acronym":"NCT07006103","lead_sponsor":"Hospital Italiano de Buenos Aires","biomarkers":" POLE","pipe":"","alterations":" ","tags":["POLE"],"overall_status":"Not yet recruiting","enrollment":" Enrollment 400","initiation":"Initiation: 06/01/2025","start_date":" 06/01/2025","primary_txt":" Primary completion: 07/01/2025","primary_completion_date":" 07/01/2025","study_txt":" Completion: 12/01/2026","study_completion_date":" 12/01/2026","last_update_posted":"2025-06-05"},{"id":"607bb9b9-82b9-4367-a752-246843270b43","acronym":"","url":"https://clinicaltrials.gov/study/NCT06998394","created_at":"2025-06-07T14:48:05.185Z","updated_at":"2025-06-07T14:48:05.185Z","phase":"Phase 2","brief_title":"A Single-Arm, Phase II Clinical Trail of Cadonilimab Combined With Chemoradiotherapy in Oligometastatic Stage IVB Cervical Cancer","source_id_and_acronym":"NCT06998394","lead_sponsor":"Xiangbo Wan","biomarkers":" PD-L1","pipe":"","alterations":" ","tags":["PD-L1"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e cisplatin • Kaitanni (cadonilimab)"],"overall_status":"Recruiting","enrollment":" Enrollment 30","initiation":"Initiation: 03/12/2025","start_date":" 03/12/2025","primary_txt":" Primary completion: 12/31/2027","primary_completion_date":" 12/31/2027","study_txt":" Completion: 12/31/2027","study_completion_date":" 12/31/2027","last_update_posted":"2025-05-31"},{"id":"d7a65642-897e-45bd-94d5-4d6f95fb2fdc","acronym":"","url":"https://clinicaltrials.gov/study/NCT06856499","created_at":"2025-06-07T14:55:53.232Z","updated_at":"2025-06-07T14:55:53.232Z","phase":"Phase 1","brief_title":"Cirtuvivint/Olaparib in Breast Cancer Susceptibility Gene/Homologous Recombination Deficiency Platinum Resistant Ovarian Cancer","source_id_and_acronym":"NCT06856499","lead_sponsor":"University of Colorado, Denver","biomarkers":" BRCA","pipe":"","alterations":" ","tags":["BRCA"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Lynparza (olaparib) • cirtuvivint (SM08502)"],"overall_status":"Not yet recruiting","enrollment":" Enrollment 50","initiation":"Initiation: 12/01/2025","start_date":" 12/01/2025","primary_txt":" Primary completion: 07/01/2027","primary_completion_date":" 07/01/2027","study_txt":" Completion: 07/01/2029","study_completion_date":" 07/01/2029","last_update_posted":"2025-05-28"},{"id":"4d358bf9-7717-49a2-94ba-504711885d91","acronym":"PERSONA-Ovary","url":"https://clinicaltrials.gov/study/NCT06972693","created_at":"2025-09-07T01:36:12.539Z","updated_at":"2025-09-07T01:36:12.539Z","phase":"Phase 4","brief_title":"NGS-based Germline and Somatic Genetic Test in Ovarian Carcinoma","source_id_and_acronym":"NCT06972693 - PERSONA-Ovary","lead_sponsor":"European Institute of Oncology","biomarkers":" BRCA2 • BRCA","pipe":"","alterations":" ","tags":["BRCA2 • BRCA"],"overall_status":"Active, not recruiting","enrollment":" Enrollment 323","initiation":"Initiation: 06/12/2018","start_date":" 06/12/2018","primary_txt":" Primary completion: 12/30/2025","primary_completion_date":" 12/30/2025","study_txt":" Completion: 12/30/2025","study_completion_date":" 12/30/2025","last_update_posted":"2025-05-15"}]